Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma - 09/09/11
Abstract |
Background: The serum concentration of soluble a chain of the interleukin-2 receptor (sIL-2R) correlates with tumor burden in cutaneous T-cell lymphoma (CTCL). Therefore the sIL-2R level may be useful to monitor the condition of patients treated with extracorporeal photopheresis or other treatments. Objective: Our goal was to determine the utility of serum sIL-2R as a test in monitoring of patients with advanced CTCL. Methods: Serum sIL-2R was measured serially in 36 patients with advanced CTCL treated with extracorporeal photopheresis and other modalities (interferon alfa, methotrexate, topical nitrogen mustard, electron beam). Results: Serum concentrations of sIL-2R as well as lactate dehydrogenase (LDH) correlated strongly with lymph node size, but only sIL-2R correlated significantly with the severity of skin manifestations in erythrodermic patients. In addition, serum sIL-2R, but not LDH, was significantly higher in patients with nodal involvement. The level of sIL-2R also was significantly higher in patients with large-cell transformation in the skin or lymph nodes compared with patients without transformed disease. During treatment, serum concentrations of both serum sIL-2R and LDH correlated with changes in clinical status, but only sIL-2R showed statistically significant differences in mean levels for different relative global response scores. Pretreatment levels of both sIL-2R and LDH correlated significantly with survival, but only sIL-2R retained significance when both were entered into the Cox proportionate hazards model. Conclusion: The concentration of serum sIL-2R correlates well with disease status and is more useful than LDH or Sézary cell counts to monitor clinical change in patients with advanced CTCL. Moreover, our data suggest that sIL-2R is produced at a relatively low rate by tissue-based lymphoma cells, and that large-cell transformation in CTCL results in marked increase in sIL-2R production in some patients. (J Am Acad Dermatol 1998;38:207-20.)
Le texte complet de cet article est disponible en PDF.Plan
Supported by the Leonard and Ruth Levine Skin Research Fund and the Brady Cancer Research Institute (to E. C. V.), grants from the National Institutes of Health Nos. AR40404 (to R. D. B.) and CA55017 (to S. R. L.), and the Department of Veterans Affairs No. AR1710 (to S. R. L.). |
|
Reprint requests: Eric Vonderheid, MD, Department of Dermatology, Allegheny University, Mailstop 478, Broad and Vine Streets, Philadelphia, PA 19102. |
|
16/1/87493 |
Vol 38 - N° 2
P. 207-220 - février 1998 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?